Medivation MDVN shares are up more than 5 percent Thursday following some bullish comments from Jefferies' Biren Amin.
The comments follow recent investor meetings with Medivation management which left Amin feeling like "the state of the Xtandi franchise and the company's outlook has
never appeared brighter." The analyst now believes his "previous Q4 '13 PREVAIL interim
timeline estimates may have been conservative, and our new calculation
suggests data could arrive as soon as July '13."
Amin is expecting favorable PREVAIL interim data.
Jefferies reiterated a Buy rating and $64 price target on shares of Medivation.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in